Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Sincere Co. Ltd. (7782.T)
Tokyo, JP
Sincere Co., LTD. manufacture and sells contact lenses in Japan. It operates through three segments: Contact Lens, Consulting, and System business. The company also engages in consulting on medical hair removal clinic management, as well as the design, development, sale, and maintenance of package systems for the reuse industry. In addition, it provides management support for medical institutions, medical related businesses, and elderly facility management. The company was incorporated in 2008 and is headquartered in Tokyo, Japan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.39% | -2.96% | -8.58% | -11.98% | -19.01% | -16.14% | -27.55% | -22.83% | -39.14% | -42.64% | -42.64% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Specialties: +8.3%+14.0% ★ Q1'26: +24.1% (vs Q1'25)
-
EPS growth Medical - Specialties: +10.1%-13.6% Q1'26: -24.1% (vs Q1'25)
-
FCF margin FCF growth · Medical - Specialties: +51.3%+5.5% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Medical - Specialties: +12.6%+7.0% Q1'26: +7.4% (vs Q1'25)
-
ROIC Medical - Specialties: +6.6%+11.1% ★ Q1'26: +12.7% (vs Q1'25)
-
Share dilution Medical - Specialties: 0.0%+1.6% Q1'26: +2.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×2.96× Q1'26: 2.72× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
|---|---|---|---|---|
| Revenue |
4.34B
est: 4.37B (-0.5%)
|
4.18B
est: 4.15B (+0.8%)
|
4.37B
est: 4.31B (+1.4%)
|
4.19B
est: 4.48B (-6.4%)
|
| EBITDA |
359.58M
est: 238.68M (+50.7%)
|
36.52M
est: 226.76M (-83.9%)
|
168.33M
est: 235.56M (-28.5%)
|
232.66M
est: 244.69M (-4.9%)
|
| EBIT |
345.40M
est: 218.96M (+57.7%)
|
26.83M
est: 208.02M (-87.1%)
|
158.17M
est: 216.10M (-26.8%)
|
218.43M
est: 224.47M (-2.7%)
|
| Net Income |
219.18M
est: 259.94M (-15.7%)
|
15.85M
est: 46.62M (-66.0%)
|
76.31M
est: 88.14M (-13.4%)
|
142.33M
est: 113.68M (+25.2%)
|
| SGA |
995.32M
est: 1.10B (-9.7%)
|
1.23B
est: 1.05B (+17.1%)
|
1.17B
est: 1.09B (+8.0%)
|
1.13B
est: 1.13B (-0.3%)
|
| EPS |
32.60
est: 40.70 (-19.9%)
|
2.37
est: 7.30 (-67.5%)
|
12.29
est: 13.80 (-10.9%)
|
22.92
est: 17.80 (+28.8%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-14 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-13 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-12 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-11 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-08 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-07 | B | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-05-01 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-30 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-28 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-27 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ken Nakamura | President, Executive Officer & Chairman | — | male |
| Masamoto Kimura | Executive Officer & GM of Second Sales Department | — | — |
| Shinichi Arai | Executive Officer, GM of Administration Department & Director | — | male |
| Takako Kondo | Executive Officer & GM of Pharmaceutical Affairs Department | — | — |
| Toru Taniguchi | Executive Officer & GM of Corporate Planning Office | — | — |
| Toshiyuki Aso | Executive Officer & Marketing Manager | — | — |
| Yoshio Shinbo | Executive Officer & GM of First Sales Department | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 7782.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
